Back to Atlas
BSemi-durableStandard research/education caution
CMP-0652
Research chemical/reference listing
Lobradimil
Nootropic / cognitive
Cognition, mood, neuroprotection, or neuroplasticity support
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Nootropic / neuroactive compound
- Primary mechanism
- Neurotransmitter, neurotrophic, or plasticity pathway modulation
- Primary market use
- Nootropic / cognitive
Pharmacology
- Molecular weight (Da)
- 1098.28
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~2–12 h small-molecule class estimate
- Route tags
- Route-dependent / verify
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 8 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Stackability
Place in nootropic comparison clusters; track acute vs durable cognitive adaptation.
Notes
Lobradimil (RMP 7), a synthetic bradykinin analog, is a potent and selective bradykinin B2 receptor agonist ( K i : 0.54 nM). Lobradimil increases the permeability of the BBB. Lobradimil can be used in the research of brain tumors.